Evidence map›Paper›PMID 29522171›Full record

ArticleBrain : a journal of neurology2018

Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing.

Jasmeer P Chhatwal, Aaron P Schultz, Keith A Johnson, Trey Hedden, Sehily Jaimes, Tammie L S Benzinger, Clifford Jack, Beau M Ances, John M Ringman, Daniel S Marcus and 21 more

Abstract read
In one paragraph

Article in Brain : a journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Plasma biomarkers as core mediators in functional network abnormalities: Evidence from a two-cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  9. Article
  10. A whole-brain functional connectivity model of Alzheimer's disease pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  11. Review
  12. Review
  13. Multivariate word properties in fluency tasks reveal markers of Alzheimer's dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  14. Article
  15. Article
  16. Review
  17. Dissociable Effects of Alzheimer's Disease-Related Cognitive Dysfunction and Aging on Functional Brain Network Segregation.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Jasmeer P ChhatwalDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Aaron P SchultzDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Keith A JohnsonDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Trey HeddenAthinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA 02129, USA.
Sehily JaimesDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Tammie L S BenzingerDepartment of Radiology, Section of Neuroradiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Clifford JackDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Beau M AncesMallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO 63110, USA.
John M RingmanDepartment of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Daniel S MarcusDepartment of Radiology, Section of Neuroradiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Bernardino GhettiDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Martin R FarlowDepartment of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Adrian DanekDepartment of Neurology, Ludwig-Maximilians Universität, Postbox 701260, 81377 Munich, Germany.
Johannes LevinGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Igor YakushevGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Christoph LaskeGerman Center for Neurodegenerative Diseases (DZNE), 72076 Tuebingen, Germany.
Robert A KoeppeDepartment of Radiology, University of Michigan, Ann Arbor, MI 48109, USA.
Douglas R GalaskoDepartment of Neurology and Perlman Neurology Clinic, University of California at San Diego, La Jolla, CA 92093, USA.
Chengjie XiongDivision of Biostatistics, Washington University School of Medicine, St. Louis, MO 63110, USA.
Colin L MastersFlorey Institute of Neuroscience, University of Melbourne, Parkville, Victoria 3010, Australia.
Peter R SchofieldNeuroscience Research Australia, Sydney NSW 2031, Australia.
Kirsi M KinnunenDementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London WC1N 3BG, UK.
Stephen SallowayButler Hospital, Providence, RI 02906, USA.
Ralph N MartinsCentre of Excellence for Alzheimer's Disease Research, School of Medical Sciences, Edith Cowan University, Joondalup, WA 6027, Australia.
Eric McDadeDepartment of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Nigel J CairnsDepartment of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Virginia D BucklesDepartment of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.
John C MorrisDepartment of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Randall BatemanDepartment of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Reisa A SperlingDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Dominantly Inherited Alzheimer Network

Funding

Imaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
Vascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rebecca E Amariglio · 2010 to 2026
$50.2M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2005 to 2025
$49.5M
VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ARANDA, MARIA P. · 1985 to 2019
$41.0M
Dominantly Inherited Alzheimer NetworkUF1AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2014 to 2017
$21.6M
Washington University Institute of Clinical and Translational Sciences (KL2) KL2TR002346 · NCATS · WASHINGTON UNIVERSITY · PI Dominic N Reeds · 2017 to 2026
$14.0M
Washington University Institute of Clinical and Translational Sciences (KL2)KL2RR024994 · NCRR · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2007 to 2011
$8.6M
proj 3 - NINDS INSTIUTIONAL CENTER CORE GRANTS TO SUPPORT NEUROSCIENCE RESEARP30NS048056 · NINDS · WASHINGTON UNIVERSITY · PI MARCUS, DANIEL SCOTT · 2004 to 2014
$7.4M
Imaging CoreU01AG032438 · NIA · WASHINGTON UNIVERSITY · PI MARCUS, DANIEL SCOTT · 2008 to 2009
$6.1M
Tau, amyloid, & white matter burden interact to impact brain networks in preclinical Alzheimer’s diseaseR01AG053509 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HEDDEN, JULIUS C · 2016 to 2020
$4.1M
NINDS CENTER CORE FOR BRAIN IMAGINGP30NS098577 · NINDS · WASHINGTON UNIVERSITY · PI HERSHEY, TAMARA G, MARCUS, DANIEL SCOTT · 2016 to 2019
$2.4M
NCATS NIH HHS KL2 TR002346NCRR NIH HHS KL2 RR024994NIA NIH HHS K01 AG040197NIA NIH HHS K23 AG049087NIA NIH HHS K24 AG035007NIA NIH HHS P01 AG026276NIA NIH HHS P01 AG036694NIA NIH HHS P50 AG005142NIA NIH HHS P50 AG005681NIA NIH HHS R01 AG053509NIA NIH HHS U01 AG032438NIA NIH HHS U19 AG032438NIA NIH HHS UF1 AG032438NINDS NIH HHS P30 NS048056NINDS NIH HHS P30 NS098577
6 · The paper itself

Abstract

Converging evidence from structural, metabolic and functional connectivity MRI suggests that neurodegenerative diseases, such as Alzheimer's disease, target specific neural networks. However, age-related network changes commonly co-occur with neuropathological cascades, limiting efforts to disentangle disease-specific alterations in network function from those associated with normal ageing. Here we elucidate the differential effects of ageing and Alzheimer's disease pathology through simultaneous analyses of two functional connectivity MRI datasets: (i) young participants harbouring highly-penetrant mutations leading to autosomal-dominant Alzheimer's disease from the Dominantly Inherited Alzheimer's Network (DIAN), an Alzheimer's disease cohort in which age-related comorbidities are minimal and likelihood of progression along an Alzheimer's disease trajectory is extremely high; and (ii) young and elderly participants from the Harvard Aging Brain Study, a cohort in which imaging biomarkers of amyloid burden and neurodegeneration can be used to disambiguate ageing alone from preclinical Alzheimer's disease. Consonant with prior reports, we observed the preferential degradation of cognitive (especially the default and dorsal attention networks) over motor and sensory networks in early autosomal-dominant Alzheimer's disease, and found that this distinctive degradation pattern was magnified in more advanced stages of disease. Importantly, a nascent form of the pattern observed across the autosomal-dominant Alzheimer's disease spectrum was also detectable in clinically normal elderly with clear biomarker evidence of Alzheimer's disease pathology (preclinical Alzheimer's disease). At the more granular level of individual connections between node pairs, we observed that connections within cognitive networks were preferentially targeted in Alzheimer's disease (with between network connections relatively spared), and that connections between positively coupled nodes (correlations) were preferentially degraded as compared to connections between negatively coupled nodes (anti-correlations). In contrast, ageing in the absence of Alzheimer's disease biomarkers was characterized by a far less network-specific degradation across cognitive and sensory networks, of between- and within-network connections, and of connections between positively and negatively coupled nodes. We go on to demonstrate that formalizing the differential patterns of network degradation in ageing and Alzheimer's disease may have the practical benefit of yielding connectivity measurements that highlight early Alzheimer's disease-related connectivity changes over those due to age-related processes. Together, the contrasting patterns of connectivity in Alzheimer's disease and ageing add to prior work arguing against Alzheimer's disease as a form of accelerated ageing, and suggest multi-network composite functional connectivity MRI metrics may be useful in the detection of early Alzheimer's disease-specific alterations co-occurring with age-related connectivity changes. More broadly, our findings are consistent with a specific pattern of network degradation associated with the spreading of Alzheimer's disease pathology within targeted neural networks.

Indexed as

AgingBrain MappingAdultAgedAged, 80 and overAlzheimer DiseaseAniline CompoundsCognition DisordersFemaleFluorodeoxyglucose F18HumansMagnetic Resonance ImagingMaleMiddle AgedModels, NeurologicalNeural Pathways2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAniline CompoundsFluorodeoxyglucose F18Thiazoles

Identifiers

PMID29522171
PMCPMC5917745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.